Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects

Next Previous
Trial Profile

Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Jan 2018

At a glance

  • Drugs Huperzine A (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors Biscayne Neurotherapeutics

    • Most Recent Events

    • 16 Jan 2018 Status changed from recruiting to completed.
    • 19 Oct 2017 Results presented in a Biscayne Neurotherapeutics media release.
    • 19 Oct 2017 Results from this trial will be presented at the 8th Annual Sofinnova Japan Biopharma Partnering Conference, according to a Biscayne Neurotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top